Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 13/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | GAA | P10253 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26104327 | 0.91 | MEN1 (1.00) | KAT6AMEN1KMT2AGAACYP3A4 | |
| SCHEMBL6400145 | 0.90 | KAT6A (0.81) | KAT6AMEN1KMT2AGAACYP3A4 | |
| SCHEMBL7151474 | 0.88 | KAT6A (0.78) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL20233361 | 0.88 | KAT6A (0.78) | KAT6AMEN1KMT2AGAAHTT | |
| SCHEMBL6396355 | 0.88 | KAT6A (0.78) | KAT6AMEN1KMT2AGAACYP3A4 | |
| SCHEMBL20233293 | 0.88 | KAT6A (0.78) | KAT6AMEN1KMT2AGAACYP3A4 | |
| SCHEMBL6979280 | 0.85 | KAT6A (0.73) | KAT6AMEN1KMT2AGAACYP3A4 | |
| SCHEMBL6397060 | 0.85 | KAT6A (0.73) | KAT6AMEN1KMT2AGAACYP3A4 | |
| SCHEMBL20233128 | 0.85 | KAT6A (1.00) | KAT6AGAA | |
| SCHEMBL20233085 | 0.85 | KAT6A (0.83) | KAT6AMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111228250-B | Application of 2-benzenesulfonylamino benzamide compound in preparation of medicine for treating liver cancer | 中国医学科学院医药生物技术研究所 | 2021-02-09 | — | — | CN | claimed |
| CN-111228250-A | Application of 2-benzenesulfonylamino benzamide compound in preparation of medicine for treating liver cancer | 中国医学科学院医药生物技术研究所 | 2020-06-05 | — | — | CN | claimed |
| CN-103889953-B | Sulfamoylbenzamide derivatives as antiviral agents against hepatitis B virus infection | 巴鲁﹒S﹒布隆伯格研究所 | 2016-06-08 | — | — | CN | claimed |
| CN-103889953-A | Sulfamoylbenzamide Derivatives as Antiviral Agents Against Hepatitis B Virus Infection | INST HEPATITIS & VIRUS RES | 2014-06-25 | — | — | CN | claimed |
| EP-1928844-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2021-03-02 | — | — | US | disclosed |
| CN-111228250-B | Application of 2-benzenesulfonylamino benzamide compound in preparation of medicine for treating liver cancer | 中国医学科学院医药生物技术研究所 | 2021-02-09 | — | — | CN | disclosed |
| CN-111228250-B | Application of 2-benzenesulfonylamino benzamide compound in preparation of medicine for treating liver cancer | 中国医学科学院医药生物技术研究所 | 2021-02-09 | — | — | CN | disclosed |
| CN-111228250-B | Application of 2-benzenesulfonylamino benzamide compound in preparation of medicine for treating liver cancer | 中国医学科学院医药生物技术研究所 | 2021-02-09 | — | — | CN | disclosed |
| CN-111228250-A | Application of 2-benzenesulfonylamino benzamide compound in preparation of medicine for treating liver cancer | 中国医学科学院医药生物技术研究所 | 2020-06-05 | — | — | CN | disclosed |
| WO-2018102419-A1 | COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS | Epizyme, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2017088775-A1 | USE OF BENZENESULFONAMIDO BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | 中国医学科学院医药生物技术研究所 | 2017-06-01 | — | — | WO | disclosed |
| CN-105801582-A | Novel dihydro pteridinone derivative, preparing method thereof and application to medicine | 合肥工业大学 | 2016-07-27 | — | — | CN | disclosed |
| CN-105395532-A | Application of 2-benzenesulfonamido benzamide compound in liver injury protection and hepatic fibrosis control | INST OF MEDICINAL BIOTECHNOLOGY CHINESE ACAD OF MEDICAL SCIENCES | 2016-03-16 | — | — | CN | disclosed |
| CN-105395532-A | Application of 2-benzenesulfonamido benzamide compound in liver injury protection and hepatic fibrosis control | INST OF MEDICINAL BIOTECHNOLOGY CHINESE ACAD OF MEDICAL SCIENCES | 2016-03-16 | — | — | CN | disclosed |
| US-6387919-B1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | GLAXO WELLCOME INC. | 2002-05-14 | — | — | US | disclosed |
| US-5380944-A | Benzhydrazone derivatives as an intermediate for the production of triazole derivatives | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | COL1A1, COL2A1, COL14A1 | KAT6A 1001/4885MEN1 4667/4885KMT2A 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.